THERAtRAME, a newly funded spin-off of the University of Liege and WELBIO, is the first drug discovery platform company that aims to develop oncological drugs targeting the tRNA epitranscriptomics, capitalizing on over a decade of fundamental scientific work performed by its founders. THERAtRAME has developed proprietary technologies to screen and to validate the efficacy of small molecule inhibitors of tRNA epitranscriptomics. THERAtRAME unique technologies include on the one hand a multi-assays approach to design new specific inhibitors for tRNA epitranscriptomics, and on the other hand, a novel AI-based bioinformatics approach, developed from proprietary datasets, which aims to position its newly developed drug candidates in relevant therapeutic indications in oncology. THERAtRAME is currently developing first-in-class small molecule inhibitors for its lead program: the company is currently undergoing the pre-clinical development phases, promoting the identified chemical leads into biological and chemical optimization and validation. THERAtRAME was founded in 2022 with strategic investments of 4.5M€, shared between private and institutional investors. The THERAtRAME team is currently composed of 8 people - management (2), administration (1), chemistry (1), operational (4) - and its activities are performed in Liège, Belgium (GIGA tower- CHU).